Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007 by unknown
British Columbia, Canada, has the largest reported 
population of Cryptococcus gattii–infected persons world-
wide. To assess the impact of illness, we retrospectively 
analyzed demographic and clinical features of reported 
cases, hospitalizations, and deaths during 1999–2007. A 
total of 218 cases were reported (average annual incidence 
5.8 per million persons). Most persons who sought treat-
ment had respiratory illness (76.6%) or lung cryptococcoma 
(75.4%). Persons without HIV/AIDS hospitalized with cryp-
tococcosis were more likely than those with HIV/AIDS to 
be older and admitted for pulmonary cryptococcosis. The 
19 (8.7%) persons who died were more likely to be older 
and to have central nervous system disease and infection 
from the VGIIb strain. Although incidence in British Colum-
bia is high, the predominant strain (VGIIa) does not seem to 
cause greater illness or death than do other strains. Further 
studies are needed to explain host and strain characteristics 
for regional differences in populations affected and disease 
outcomes.
C
ryptoccocus gattii is an environmental fungus that 
emerged in a temperate climate on Vancouver Island, 
British Columbia, Canada, in 1999, causing an outbreak af-
fecting humans and animals (1,2). Previously, C. gattii had 
been reported only from primarily tropical and subtropi-
cal regions (3,4); since then, >200 human cases have been 
documented in British Columbia.
In British Columbia, C. gattii colonizes various species 
of trees and soil and has been recovered from water and air 
(5). Humans become infected by inhaling yeasts or spores. 
The primary site of infection is the lung; C. gattii can lead 
to pneumonia or formation of cryptococcomas. The infec-
tion can disseminate to most other organs, notably the central 
nervous system (CNS), where it causes meningoencephalitis 
or brain cryptococcomas (6,7). Infection is thought to occur 
mostly in immunocompetent persons, but new evidence from 
British Columbia shows that a sizeable proportion of persons 
with C. gattii have underlying immunocompromising condi-
tions (E. Galanis, L. MacDougall, unpub. data). This con-
trasts with C. neoformans, which is distributed worldwide 
and causes mostly CNS infections in immunocompromised 
persons, particularly HIV-infected persons (6,7).
Some researchers have suggested that VGIIa, the pre-
dominant strain in British Columbia, is more virulent than 
other strains found in other countries (4,8,9). Most stud-
ies of epidemiologic and clinical aspects of C. gattii have 
shown fewer illnesses and deaths from C. gattii infection 
than from C. neoformans ( 10,11); however, some have 
shown they are higher (12).
British Columbia has the largest documented popu-
lation of C. gattii–infected persons worldwide. To clarify 
the epidemiology and impact of illness caused by C. gattii 
infection, we retrospectively analyzed incidence of, hospi-
talizations for, and deaths caused by C. gattii in British Co-
lumbia from its emergence in 1999 through 2007.
Methods
Incidence was derived from cases reported to public 
health authorities. Because complete information about re-
ported cases was not available, hospitalization and death 
rates were derived from administrative registries.
Case Deﬁ  nitions
BC laboratories report persons infected with Crypto-
coccus spp. to public health authorities (population-based 
surveillance). We analyzed C. gattii infection diagnosed 
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during 1999–2007 in BC residents and reported to the BC 
Centre for Disease Control. A conﬁ  rmed case was deﬁ  ned 
as culture-conﬁ  rmed C. gattii infection based on differential 
media and genotyping (13). A probable case was deﬁ  ned 
as laboratory evidence of infection from antigen detection, 
histopathology, or microscopy in an HIV-negative person. 
For their infection to be considered a case, patients must 
have traveled to or resided in a local C. gattii–endemic area 
during the year before onset. Local C. gattii–endemic areas 
were Vancouver Island since 1999 and the greater Vancou-
ver area and Fraser Valley of the BC mainland since 2004 
(13). We deﬁ  ned a case acquired on the BC mainland as a 
conﬁ  rmed case in a person who did not travel to Vancouver 
Island or to any international C. gattii–endemic area during 
the year before illness onset.
Case-patients were classiﬁ  ed as having a respiratory 
syndrome if they reported cough or an abnormal chest ra-
diograph or had microbiologic evidence of Cryptoccocus 
in a respiratory specimen. Case-patients were classiﬁ  ed as 
having a CNS syndrome if they had abnormal brain imag-
ing or microbiologic evidence of Cryptococcus in a brain 
or cerebrospinal ﬂ  uid specimen. Case-patients with other 
presentations had microbiologic evidence of Cryptococcus 
in another organ/tissue. Case-patients who were HIV posi-
tive or had a history of invasive cancer or organ transplant 
or were on corticosteroids in the year before onset were 
considered immunocompromised.
Incidence, Epidemiology, and Clinical Characteristics
Incidence, epidemiology, and clinical characteristics 
were analyzed for conﬁ  rmed, probable, and all cases and 
compared between conﬁ  rmed and probable cases. We de-
rived incidence using annual BC population estimates. We 
calculated frequencies using the case-patients from whom 
the information was available, which varied for each ques-
tion or data point.
Hospitalizations
Hospital discharge data for International Classiﬁ  cation 
of Diseases, Ninth Revision (ICD-9), code 117.5 and Tenth 
Revision (ICD-10) code B45.X (B45.0, B45.1, B45.2, 
B45.3, B45.7, B45.8, B45.9) were obtained from the BC 
Hospital Separations/Discharge Abstract Database, which 
captures all hospital visits in the province, for 1999–2006 
(14). (British Columbia switched from ICD-9 to ICD-10 
coding in 2001.) Records with the same unique identiﬁ  er 
and age (adjusted for date of hospitalization) were consid-
ered to represent the same person because unique identiﬁ  ers 
for certain types of patients were recycled. Annual hospi-
talization rates were derived by adding the earliest hospital-
ization for each individual and dividing by the annual BC 
population. Additional hospitalizations for the same person 
were considered repeat hospitalizations.
Because ICD-9 and ICD-10 have no C. gattii-speciﬁ  c 
code, we analyzed persons hospitalized with cryptococ-
cosis without HIV/AIDS. We chose this population as a 
proxy for C. gattii infection because its hospitalization rate 
increased sharply in 1999, signaling onset of the outbreak 
(1). In addition, few (6.2%) conﬁ  rmed C. gattii–infected 
persons have HIV infection in British Columbia (E. Gala-
nis, L. MacDougall, unpub. data). HIV/AIDS was deﬁ  ned 
as ICD-9 codes V08 and 042.X (42.0, 42.1, 42.2, 42.8, 
42.9) and ICD-10 codes B20, B21, B22, B23, and B24. 
Cases of cryptococcosis were separated into those with no 
ICD code for HIV/AIDS reported on any hospitalization 
record within the study period and those with an ICD code 
for HIV/AIDS reported at least once. Among cases with an 
ICD-10 code for cryptococcosis, subcodes were analyzed. 
(Subcodes for cryptococcosis are not available in ICD-9.)
Deaths
Non-nominal data for deaths from cryptoccocal infec-
tion were obtained from BC Vital Statistics, which includes 
all deaths among BC residents (15). All deaths occurring 
during 1999–2007 for which the underlying or a contrib-
uting cause of death was noted as ICD-9 code 117.5 or 
ICD-10 code B45.X were extracted. We identiﬁ  ed deaths 
in persons with C. gattii infection by matching birth date 
with cases reported to the BC Centre for Disease Control. 
We derived annual death rates by dividing the number of 
deaths by the annual BC population.
Population Data, Analysis and Software Used, 
and Patient Consent
Population data were obtained from British Colum-
bia Statistics (16). Using the χ2 test and Fisher exact test, 
we compared independent proportions; the t test, to com-
pare means; and the Mann-Whitney test, to compare non-
normally distributed results. We used the Bonferroni cor-
rection to compare strain distribution by age group. Data 
were analyzed by using SPSS v16.0 (SPSS Inc., Chicago, 
IL, USA) and StatXact-6 v6.2.0. (StataCorp LP, College 
Station, TX, USA) Because the data were obtained from 
surveillance and administrative sources and presented in 
aggregate format, patient consent was not obtained.
Results
Incidence, Epidemiology, and Clinical Characteristics
A total of 218 cases (124 conﬁ  rmed and 94 probable) 
of  C. gattii infection were reported during 1999–2007 
(Table 1). An average of 24.2 cases was reported every 
year (5.8/million/year); cases increased steadily from 6 in 
1999 to 38 in 2006 (Figure 1). Onset did not vary by season 
or by month. Nearly three quarters (73.9%) of all case-pa-
tients lived on Vancouver Island (average annual incidence 
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rate 25.1/million). The number of cases reported per year 
reached a plateau on Vancouver Island in 2002 but has in-
creased on the mainland since 2005. Seven conﬁ  rmed cases 
were acquired on the BC mainland (1 in 2004, 2 in 2005, 3 
in 2006, and 1 in 2007).
Just over half (55.5%) of all case-patients were male. 
The mean age was 58.7 years. The incidence rate increased 
with age, with the highest age-speciﬁ  c rate in persons 70–
79 years of age.
A total of 167 (76.6%) case-patients sought treatment 
for a respiratory syndrome; 17 (7.8%), for a CNS syndrome; 
22 (10.1%), for both respiratory and CNS syndromes; and 
1 each, for a combination of skin and respiratory, skin and 
CNS, and sepsis and respiratory syndrome (Table 1). The 
most common symptoms reported in case-patients with a 
respiratory syndrome were cough, dyspnea, and chest pain. 
Case-patients with a CNS syndrome most commonly re-
ported headache, night sweats, weight loss, anorexia, and 
neck stiffness. Eighty-nine (75.4%) of the118 case-patients 
who had abnormal chest radiographs had single or multiple 
lung nodules. Sixteen (7.3%) cases were asymptomatic. 
All had a respiratory syndrome, and all who reported chest 
radiograph results had evidence of single or multiple lung 
nodules. Age, sex, and genotype did not differ signiﬁ  cantly 
from those of symptomatic cases. Ninety-eight (60.9%) 
case-patients were hospitalized. Seventy (38.0%) case-pa-
tients were considered immunocompromised; 81.4% had 
a respiratory syndrome and 5.7% had CNS signs. Being 
immunocompromised was not associated with clinical pre-
sentation (p = 0.385).
Patients with conﬁ  rmed and probable cases did not dif-
fer signiﬁ  cantly by age and sex or proportions residing on 
Vancouver Island, asymptomatic, hospitalized, or immu-
nocompromised (Table 1). Persons with conﬁ  rmed cases 
were more likely than persons with probable cases to have 
a CNS syndrome only (p = 0.001) or a CNS and respiratory 
syndrome (p<0.001) and less likely to have a respiratory 
syndrome only (p = 0.031).
Three conﬁ  rmed cases occurred in children 2, 5, and 
16 years of age. Each had a respiratory syndrome; 1 was as-
ymptomatic. All were HIV negative. Two were on inhaled 
corticosteroids. One had a chronic respiratory disease, 1 
had a genetic disorder; the third was otherwise well.
The VGIIa strain was responsible for 107 (86.3%) of 
conﬁ  rmed cases. Eight case-patients were infected with 
VGI and 9 with VGIIb. Clinical presentation did not differ 
signiﬁ  cantly by genotype. However, strains differed by pa-
tient age; case-patients >50 years of age were more likely 
to be infected with VGIIa (p = 0.002) or VGIIb (p = 0.006) 
than with VGI (Figure 2).
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Table 1. Characteristics of persons with cases of confirmed or probable Cryptococcus gattii infection, British Columbia, Canada, 1999–
2007*
Characteristic Total Confirmed Probable p value 
No. cases  218 124 94 NA
  Average incidence (million/year)  5.8 3.3 2.5 NA
  No. cases in persons living on Vancouver Island 161 (73.9)  83 (66.9)  78 (83.0)  0.177
Demographic data 
  Male sex  121 (55.5)  73 (58.9)  48 (51.1)  0.440
 Age,  y 
  Mean  58.7 58.7 58.7 0.988
  Range  2–92 2–92 12–87 NA
    Children <18 y  4 (1.8)  3 (2.4)  1 (1.1)  0.463
Clinical assessment 
  Respiratory syndrome  167 (76.6)  85 (68.5)  82 (87.2)  0.031
  CNS syndrome  17 (7.8)  16 (12.9)  1 (1.1)  0.001
  Respiratory and CNS syndrome  22 (10.1)  20 (16.1)  2 (2.1)  <0.001
  Other/unknown  12 (5.5)  3 (2.4)  9 (9.6)  NA
  Asymptomatic  16 (7.3)  6 (4.8)  10 (11.0)  0.120
Hospitalized 98 (60.9)  58 (65.2)  40 (55.6)  0.434
Immunocompromised  70 (38.0)  41 (38.7)  29 (37.2)  0.870
*Frequencies were calculated by using persons from whom information was available, which varied for each question or data point. All values given as 






























































Figure 1. Number of cases of Cryptococcus gattii infection and 
incidence rate per million population, by case-patient place of 
residence, British Columbia (BC), Canada, 1999–2007. Mainland, 
mainland BC; VI, Vancouver Island.RESEARCH
Hospitalizations
During 1999–2006, a total of 322 persons were hospi-
talized with cryptococcosis, for a total of 533 hospitaliza-
tions. A total of 191 (59.3%) persons did not have HIV/
AIDS. An average of 21.2 persons without HIV/AIDS were 
hospitalized for cryptococcosis each year; this number in-
creased steadily from 10 in 1999 to 38 in 2006 (Figure 3). 
At 5.8 hospitalizations per million BC residents, the aver-
age annual hospitalization rate was higher for cryptococ-
cosis without HIV/AIDS than with HIV/AIDS (p = 0.004) 
(Table 2). Persons with HIV/AIDS had more admissions 
per person and were hospitalized for longer periods (both 
p<0.001). Hospitalized persons without HIV/AIDS were 
less likely to be male (p = 0.007) and more likely to be 
older (p<0.001) than those with HIV/AIDS.
Among cryptococcosis hospitalizations for which an 
ICD-10 code was available, most (56.5%) hospitalizations 
for persons without HIV/AIDS were for pulmonary cryp-
tococcosis; most (77.7%) hospitalizations for persons with 
HIV/AIDS were for cerebral cryptococcosis (Table 3). Per-
sons without HIV/AIDS were more likely to be hospitalized 
with pulmonary (p<0.001) or cutaneous (p = 0.044) disease 
but less likely to be hospitalized with cerebral (p<0.001) 
or disseminated (p<0.001) disease than were persons with 
HIV/AIDS.
Deaths
During 1999–2007, 19 case-patients (case-fatality ratio 
[CFR] 8.7%) died from or with C. gattii infection, of which 
15 cases were conﬁ  rmed (CFR = 12.1%). The C. gattii–
speciﬁ  c average annual death rate, based on all deaths, was 
0.5/million. During the same period, 42 case-patients died 
with cryptococcosis and HIV/AIDS infection, for an aver-
age annual death rate of 1.1/million in British Columbia.
Thirteen (68.4%) case-patients who died were male, 
but this percentage did not signiﬁ  cantly differ from that 
of case-patients who survived (p = 0.474). Mean age at 
death was 67.6 years (range 26–91 years). Persons who 
died were older at diagnosis than survivors (p = 0.019) and 
more likely to have CNS syndrome with or without respira-
tory syndrome (p = 0.014). Ten (66.7%) persons with con-
ﬁ  rmed cases who died had an infection caused by VGIIa; 
4 (26.7%), by VGIIb; and 1 (6.7%), by VGI. Case-patients 
who died were more likely to have been infected by VGIIb 
than by the other 2 strains combined (p = 0.002).
On the basis of public health interviews and death cer-
tiﬁ  cates, 14 (73.7%) of all case-patients who died had un-
derlying medical conditions that might have increased their 
risk for death, including cancer, chronic obstructive pulmo-
nary disease, asthma, liver disease, diabetes, HIV infection, 
lung transplant, congestive heart failure, and congenital 
heart malformation. Nine (47.4%) were immunocompro-
mised; case-patients who died were not more likely than 
survivors to be immunocompromised (p = 0.267).
Discussion
We have presented a population-based assessment of 
the epidemiology and impact of illness of C. gattii infection 
in a newly endemic part of the world. Although a number 
of studies have assessed epidemiologic and clinical features 
of cryptococcosis, few have done so for C. gattii cases sep-
arately, particularly in recent years and outside Australia 
(10–12,17). Because few regions other than British Colum-
bia and France have ongoing population-based surveillance 
for cryptococcosis, most previous studies were based on 
retrospective hospital chart reviews or surveys (18).
The average annual incidence of C. gattii infection on 
Vancouver Island (25.1/million) is one of the highest in the 
world. Australia reported an annual cryptococcal infection 
incidence of 140/million in Aboriginals in Arnhemland, 
Northern Territory, in 1976–1992 (19); a total of 77.8% of 
these cases were caused by C. gattii. Papua New Guinea 
reported an annual C. gattii incidence of 42.8/million in the 
Central Province in 1993–1995, but this included cases in 
























Figure 2. Distribution of Cryptococcus gattii strains among 124 


























































































Incidence among persons without HIV/AIDS
Incidence among persons with HIV/AIDS
Figure 3. Comparison of hospitalizations for cryptococcosis among 
persons with and without HIV/AIDS, British Columbia, Canada, 
1999–2006.C. gattii, British Columbia
residents of other provinces (20). The reason for the high 
incidence in British Columbia and these other regions is 
unclear but may be due to ecologic, host, or strain-related 
characteristics.
The incidence in British Columbia increased in the 
early years of the emergence (1999–2001), either because 
of increasing awareness and reporting or a true increase in 
incidence from increased fungal concentration over time 
or gradual cumulative infection of exposed susceptible 
persons. The incidence on Vancouver Island stabilized in 
2002, but the overall BC incidence increased in 2006–
2007 because of an increased number of case-patients 
residing on the BC mainland, suggesting that the true 
number of persons exposed there may be higher than we 
estimated using our speciﬁ  c case deﬁ  nition for acquisition 
on the mainland.
Although the deﬁ  nition for a conﬁ  rmed case is more 
speciﬁ  c, all variables analyzed are similar for conﬁ  rmed 
and probable cases except clinical presentation. Cases that 
include a CNS syndrome may be more likely to be con-
ﬁ  rmed through a cerebrospinal ﬂ  uid culture than are cases 
that include respiratory syndrome, which require a more 
invasive pulmonary sample for culture conﬁ  rmation.
C. gattii incidence rates and trends in British Colum-
bia are similar to the cryptococcosis hospitalization rate for 
persons without HIV/AIDS. However, only 60.9% of C. 
gattii–infected case-patients reported being hospitalized 
for their illness. This discrepancy most likely results from 
hospitalization of persons with other immunocompromis-
ing conditions whose cryptococcal infection was caused 
by C. neoformans rather than C. gattii. Before C. gattii 
emerged in 1999, an average of 11 persons were hospital-
ized with cryptococcosis without HIV/AIDS in British Co-
lumbia each year (1). This average is similar to the annual 
incidence of cryptococcosis in persons without HIV/AIDS 
in non–C. gattii–endemic regions (7,21–23). Therefore, the 
true C. gattii hospitalization rate is probably lower than that 
reported here. Lack of a C. gattii–speciﬁ  c ICD code and 
exclusion of persons hospitalized before 1999 limited our 
assessment.
Most (90.8%) C. gattii–infected persons sought treat-
ment for respiratory syndrome with or without neurologic 
ﬁ  ndings. Respiratory presentations and pulmonary crypto-
coccomas are commonly associated with C. gattii or cryp-
tococcal infections in immunocompetent patients (10,24). 
Only 18.3% of BC cases had evidence of CNS involvement 
initially, which contrasts with an Australian study of hos-
pitalized patients in which 85% of 20 C. gattii–infected pa-
tients had meningitis and a nationwide survey in Colombia 
in which 93.3% of 30 had neurologic ﬁ  ndings (10,17). Also 
in contrast to other authors, we found that case-patients 
without HIV/AIDS were admitted less often and hospital-
ized for less time than those with HIV/AIDS (12). These 
differences may be due to the timing of data collection in 
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Table 2. Characteristics of hospitalizations and demographic data for 322 persons hospitalized for cryptococcosis, British Columbia,
Canada, 1999–2006 
Characteristic Cryptococcosis without HIV/AIDS Cryptococcosis with HIV/AIDS p value
No. hospitalizations 266 267
No. case-patients 191 131
Incidence* 5.8 3.9 0.004
No. admissions per case-patient, median (range) 1 (1–7)  3 (1–11)  <0.001
Length of stay, d, median (range) 8 (0–142)  14 (1–288)  <0.001
Demographic data
  Male sex, % 56.5 82.4 0.007
 Age,  y
  Mean 57.9 40.3 <0.001
  Range 1–91 6–75
*Average annual hospitalization rate per million British Columbia population. 
Table 3. ICD-10 codes for cryptococcosis hospitalizations, British Columbia, Canada, 1999–2006 (N = 322)* 
Condition (ICD-10 code)
Cryptococcosis without HIV/AIDS, 
no. (%)†
Cryptococcosis with HIV/AIDS, 
no. (%)† p value
Pulmonary cryptococcosis (B45.0)  130 (56.5)  13 (6.7)  <0.001
Cerebral cryptococcosis (B45.1)  63 (27.4)  150 (77.7)  <0.001
Cutaneous cryptococcosis (B45.2)  7 (3.0)  1 (0.5)  0.044
Osseous cryptococcosis (B45.3)  1 (0.4)  0 ND
Disseminated cryptococcosis (B45.7)  5 (2.2)  22 (11.4)  <0.001
Other forms of cryptococcosis (B45.8)  11 (4.8)  6 (3.1)  0.289
Cryptococcus, unspecified (B45.9)  13 (5.7)  12 (6.2)  0.834
Missing ICD-10 code  36 74
Total 266 267
*ICD-10, International Classification of Diseases, tenth revision; ND, not determined. 
†Total hospitalizations minus hospitalizations for which ICD code is missing. RESEARCH
the progression of disease (which may have occurred ear-
lier in British Columbia); the fact that the case-patients in 
the Australian studies were all hospitalized (and probably 
more seriously ill); and differences in study methods, medi-
cal practices, and strain characteristics. Our analysis was 
limited by the self-reported nature of the data, which lacked 
speciﬁ  city and detail.
Published estimates of CFRs vary widely; from 0% of 
20 cases to 15% of 26 cases with CNS disease in Australia 
(10,12). The CFR in British Columbia (8.7%) is probably 
a more stable estimate given the large number of case-pa-
tients for whom information was available and, possibly, 
the different strain distribution. BC case-patients who died 
were more likely to be older, have CNS disease, and be 
infected with VGIIb. The small numbers preclude assess-
ment of whether death was independently associated with 
age or genotype. Other studies also have found that CNS 
disease and age increase the risk for death (12,25).
Of C. gattii-infected persons, 7.3% (9.6% of cases with 
a respiratory syndrome) were asymptomatic. The few stud-
ies describing this ﬁ  nding report that approximately one 
third of pulmonary cryptococcal cases are asymptomatic 
(24,26,27). The much lower proportion of asymptomatic 
cases in British Columbia may result from species or strain 
differences or diagnostic and reporting practices.
In British Columbia, 3 (2.4%) persons with conﬁ  rmed 
cases were <18 years of age. In most C. gattii–endemic 
areas except northern Brazil, cryptococcosis in children 
is rarely reported (12,17,28–30). Two of the BC pediat-
ric case-patients had underlying conditions affecting their 
lungs and were on inhaled corticosteroids. Diminished re-
spiratory function or some level of immunocompromise 
may be necessary for children to become infected with 
C. gattii. The natural history of disease remains unclear; 
symptomatic disease may be associated with recent expo-
sure, prolonged incubation, or reactivation of latent disease 
(31,32). In British Columbia, the incidence is highest in the 
70–79-year age group, which may be linked to underlying 
medical conditions or to decreasing age-related cellular 
immunity, both of which could lead to acute infection or 
reactivation of latent disease.
Mouse models show that VGIIa may be more virulent 
than VGI and C. neoformans (9). Although C. gattii inci-
dence is comparatively high in British Columbia, we could 
not ﬁ  nd evidence that VGIIa causes more severe illness and 
a higher death rate than do other strains or C. neoformans. 
In British Columbia, persons hospitalized with cryptococ-
cosis and HIV/AIDS (a proxy for C. neoformans infection) 
were more likely than those without HIV/AIDS to be hospi-
talized with severe disease. The death rate for case-patients 
with HIV/AIDS was twice as high as that for persons with 
C. gattii infection. In British Columbia, C. gattii–infected 
persons were less likely to present with CNS disease and no 
more likely to die from their infection than those in Austra-
lia, most of which is caused by VGI. In addition, we found 
that VGIIb infections may be more likely to be associated 
with a fatal outcome than VGIIa or VGI infections, either 
directly or because they affect older persons. This ﬁ  nding 
might be related to a strain-speciﬁ  c ability to reactivate. 
This association merits further study. To further assess the 
pathogenicity of Cryptococcus strains, common genotyp-
ing methods need to be used routinely to compare strains 
and outcomes internationally.
Evidence is increasing that C. gattii affects different 
populations and has a different clinical presentation and 
outcome than C. neoformans infection. Whether this is due 
to strain or host characteristics remains unclear. Speciation 
of Cryptococcus and laboratory-based surveillance should 
be considered for all areas where C. gattii is known to be, 
or is possibly, endemic. Where the disease is not reportable, 
a C. gattii–speciﬁ  c ICD code would allow surveillance of 
hospitalized case-patients. Raising awareness among physi-
cians is necessary to ensure appropriate specimens are col-
lected for culture and diagnoses are accurately reported.
Understanding of the progression of C. gattii infection 
and disease is lacking. C. gattii–speciﬁ  c serologic tools and 
long-term studies are needed to better understand natural 
progression and factors that impact outcome to better man-
age the risk associated with C. gattii and patients affected 
by it.
We have provided evidence of substantial C. gattii–
related illness and of continued yet limited acquisition on 
the BC mainland since 2004. With its recent identiﬁ  cation 
in the US Paciﬁ  c Northwest, standardized laboratory-based 
surveillance and sharing of epidemiologic data are neces-
sary to increase understanding of how and where this elu-
sive pathogen spreads (13,33–35).
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